Automatic Segmentation of Polycystic Liver (ASEPOL)

May 23, 2019 updated by: Hospices Civils de Lyon

Automatic Segmentation by a Convolutional Neural Network (Artificial Intelligence - Deep Learning) of Polycystic Livers, as a Model of Multi-lesional Dysmorphic Livers

Assessing the volume of the liver before surgery, predicting the volume of liver remaining after surgery, detecting primary or secondary lesions in the liver parenchyma are common applications that require optimal detection of liver contours, and therefore liver segmentation.

Several manual and laborious, semi-automatic and even automatic techniques exist.

However, severe pathology deforming the contours of the liver (multi-metastatic livers...), the hepatic environment of similar density to the liver or lesions, the CT examination technique are all variables that make it difficult to detect the contours. Current techniques, even automatic ones, are limited in this type of case (not rare) and most often require readjustments that make automatisation lose its value.

All these criteria of segmentation difficulties are gathered in the livers of hepatorenal polycystosis, which therefore constitute an adapted study model for the development of an automatic segmentation tool.

To obtain an automatic segmentation of any lesional liver, by exceeding the criteria of difficulty considered, investigators have developed a convolutional neural network (artificial intelligence - deep learning) useful for clinical practice.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Lyon, France, 69437
        • Recruiting
        • Service de radiologie - Pavillon B - Cellule Recherche imagerie, Hôpital Edouard Herriot (HCL)
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pierre-Jean VALETTE, MD, Prof.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with hepato-renal polycystosis, with or without surgery

Description

Inclusion Criteria:

  • Patients ≥ 18 years old
  • Patients with hepato-renal polycystosis, with or without surgery
  • Patients with at least one abdominal-pelvic CT scan without injection or with injection between January 1, 2016 and August 2018
  • Patients with good quality and available images

Exclusion Criteria:

  • Patients with no CT scan images available
  • Patients with bad quality of CT scan images

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Neuronal network Training group

The following radiological variables, related to each CT examinations, will be collected for each patient:

  • Injection modalities (without injection, injected)
  • Major hepatectomy surgery
  • Importance of hepatic dysmorphia
  • Presence of intraperitoneal fluid effusion
  • Presence of renal polycystosis (especially on the right side).
The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.

An initial training phase of the artificial intelligence network will be carried out :

- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals

An initial training phase of the artificial intelligence network will be carried out :

- Use of computer data to drive the artificial intelligence network.

Neuronal network Validation group

The following radiological variables, related to each CT examinations, will be collected for each patient:

  • Injection modalities (without injection, injected)
  • Major hepatectomy surgery
  • Importance of hepatic dysmorphia
  • Presence of intraperitoneal fluid effusion
  • Presence of renal polycystosis (especially on the right side).
The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.

A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :

- Carried out by an intern at the Lyon hospitals

A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :

- Carried out by the neural network

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Test of automatic segmentation by the convolutional neural network on these group and collection of data set
Time Frame: At 4 months after randomization

Development of an automatic segmentation tool for highly dysmorphic polycystic livers as a prerequisite for segmentation of any type of multi-lesional livers that are difficult to segment, in order to facilitate lesion detection and volume measurement in clinical practice.

Randomisation of the patient into two data groups, one for training the other for Validating the convolutional neural network (artificial intelligence)

  • Manual segmentation of polycystic livers of the 1st training group and deep learning of convolutional neural network
  • Manual segmentation of polycystic livers of 2nd validation group
  • Test of automatic segmentation by the convolutional neural network on these group and collection of data set
At 4 months after randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2019

Primary Completion (Anticipated)

July 1, 2019

Study Completion (Anticipated)

September 1, 2019

Study Registration Dates

First Submitted

May 21, 2019

First Submitted That Met QC Criteria

May 21, 2019

First Posted (Actual)

May 23, 2019

Study Record Updates

Last Update Posted (Actual)

May 28, 2019

Last Update Submitted That Met QC Criteria

May 23, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ASEPOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polycystic Liver Disease

Clinical Trials on Anonymized CT examinations

3
Subscribe